Join Growin Stock Community!

向榮生技6794.TW Overview

TW StockBiotech. & Medical
(No presentation for 6794)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

向榮生技（6794）Overall Performance

向榮生技（6794）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

向榮生技（6794） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

向榮生技（6794）Key Information

向榮生技（6794）Profile

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan. It develops ELIXCYTE, which is in Phase 2 clinical trials for the treatment of osteoarthritis and chronic kidney disease. The company offers UnicoVial, a cryotube and drug container for cell therapy products, as well as provides testing services. UnicoCell Biomed Co., Ltd. is based in Taipei, Taiwan.

向榮生技（6794）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
156.62
PB Ratio
7.46
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
67.65%
Net Margin
-309.55%
Revenue Growth (YoY)
2.57%
Profit Growth (YoY)
8.60%
3-Year Revenue Growth
-13.94%
3-Year Profit Growth
-15.92%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
156.62
PB Ratio
7.46
Price-to-FCF
-
Gross Margin
67.65%
Net Margin
-309.55%
Revenue Growth (YoY)
2.57%
Profit Growth (YoY)
8.60%
3-Year Revenue Growth
-13.94%
3-Year Profit Growth
-15.92%
default symbol

6794

向榮生技

85.20D

-2.93%

(-0.03)

  • When is 6794's latest earnings report released?

    The most recent financial report for 向榮生技 (6794) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6794's short-term business performance and financial health. For the latest updates on 6794's earnings releases, visit this page regularly.

  • What is the operating profit of 6794?

    According to the latest financial report, 向榮生技 (6794) reported an Operating Profit of -31.08M with an Operating Margin of -593.96% this period, representing a decline of 100.63% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6794's revenue growth?

    In the latest financial report, 向榮生技 (6794) announced revenue of 5.23M, with a Year-Over-Year growth rate of -64.35%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6794 have?

    At the end of the period, 向榮生技 (6794) held Total Cash and Cash Equivalents of 49.51M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6794 go with three margins increasing?

    In the latest report, 向榮生技 (6794) did not achieve the “three margins increasing” benchmark, with a gross margin of 58.7%%, operating margin of -593.96%%, and net margin of -482.55%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6794's profit trajectory and future growth potential.

  • Is 6794's EPS continuing to grow?

    According to the past four quarterly reports, 向榮生技 (6794)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.42. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6794?

    向榮生技 (6794)'s Free Cash Flow (FCF) for the period is 822K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 31.5% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.